文献速递特殊人群用药治疗药物监测与药物基因组学

生理药代动力学模型评估CYP2B6基因型对儿童、母亲及哺乳婴儿依非韦伦暴露的影响

Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants.
PubMed 文献 · Clin Pharmacol Ther · 2023-05-10

该研究应用已验证的依非韦伦生理药代动力学(PBPK)模型,预测不同CYP2B6基因型下儿童(低至3月龄)、母亲及哺乳婴儿的依非韦伦暴露,并评估WHO(≥3岁)和FDA(≥3月龄)体重剂量方案的 adequacy。模型预测与观察数据合理一致,捕获了母婴复合基因型从GG/GG到TT/TT婴儿暴露升高的临床显著趋势,表明PBPK模型可用于脆弱人群研究设计及基于发育生理和药物遗传学的剂量指导。

要点

  • PBPK模型能合理预测不同CYP2B6基因型下母亲、哺乳婴儿及≥3月龄儿童的依非韦伦药代动力学参数。
  • 模型捕获了母婴复合CYP2B6基因型从GG/GG到TT/TT时婴儿依非韦伦暴露升高的临床显著趋势。
  • PBPK模型可用于脆弱人群研究设计及基于发育生理和药物遗传学的剂量指导。

核心结论

  • PBPK模型可合理预测不同CYP2B6基因型下儿童、母亲及哺乳婴儿的依非韦伦暴露,并支持基于发育生理和药物遗传学的剂量设计。

研究设计与样本

  • 应用先前报道并已验证的依非韦伦PBPK模型,该模型描述多次给药期间CYP3A4和CYP2B6介导的自身诱导,预测儿童(低至3月龄)、母亲及哺乳婴儿在不同CYP2B6基因型下的暴露。

主要发现

  • 母亲、哺乳婴儿及≥3月龄儿童的预测药代动力学参数与观察数据合理一致,与CYP2B6基因型无关。
  • PBPK模型合理捕获了婴儿依非韦伦暴露随母婴复合CYP2B6基因型从GG/GG到TT/TT升高的临床显著趋势。

关键数值与推荐

  • 模拟评估了当前WHO(≥3岁)和FDA(≥3月龄)基于体重的依非韦伦儿童剂量方案在不同CYP2B6基因型下的 adequacy。

临床怎么用

  • 临床可参考PBPK模型预测结果,结合CYP2B6基因型和发育生理评估儿童、母亲及哺乳婴儿的依非韦伦暴露与剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The antiretroviral drug efavirenz remains widely used in children and mothers during breastfeeding in tuberculosis-endemic areas. Evaluating the safety of efavirenz during breastfeeding requires an understanding of its pharmacokinetics (PKs) in breast milk, its exposure in the breastfed infant, and the potential influence of polymorphisms in drug disposition genes. The interplay of these factors between the mother and the nursing infant is a complex scenario that can be readily investigated using physiologically-based PK (PBPK) modeling. A verified PBPK model for efavirenz describing the CYP3A4- and CYP2B6-mediated auto-induction during multiple dosing was reported previously and was applied in this study to predict the exposure of efavirenz in vulnerable populations, including children (down to the age of 3 months), mothers, and breastfeeding infants, accounting for the various CYP2B6 genotypes. Predicted pharmacokinetic parameters for mothers, breastfeeding infants, and children aged ≥ 3 months were reasonably consistent with observed data, irrespective of CYP2B6 genotype. The clinically significant trend toward higher infant efavirenz exposure from GG/GG to TT/TT composite maternal/infant CYP2B6 genotypes was captured reasonably well by the PBPK model. Thereafter, simulations were performed to determine the adequacy of the current World Health Organization (WHO; ≥ 3 years) and the US Food and Drug Administration (FDA; ≥ 3 months) weight-based dosing regimens for efavirenz in children according to CYP2B6 genotype. The findings of this study indicate that PBPK models can be used in designing studies in vulnerable populations and providing guidance on optimal doses based on developmental physiology and pharmacogenetics.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pan X, Rowland Yeo K. Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. Clin Pharmacol Ther. 2023. PMID: 37078251. doi:10.1002/cpt.2912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。